Stockreport

JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF In November 2025, Intellia announced that in the MAGNITUDE trial (NCT06128629) of nexiguran ziclumeran, an in vivo CRISPR therapy, for transthyretin (ATTR) amyloidosis, [Read more]